Von dem Buch BACE - Lead Target for Orchestrated Therapy of Alzheimer's Disease haben wir 2 gleiche oder sehr ähnliche Ausgaben identifiziert!
Falls Sie nur an einem bestimmten Exempar interessiert sind, können Sie aus der folgenden Liste jenes wählen, an dem Sie interessiert sind:
100%: Varghese John: BACE - Lead Target for Orchestrated Therapy of Alzheimer's Disease (ISBN: 9780470594070) in Englisch, auch als eBook.Nur diese Ausgabe anzeigen…
60%: a cura di: Varghese John: BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease Format: Cloth/WebSite Associated w/Book (ISBN: 9780470293423) 2010, Erstausgabe, in Englisch, Broschiert.Nur diese Ausgabe anzeigen…
BACE - Lead Target for Orchestrated Therapy of Alzheimer's Disease
10 Angebote vergleichen
Bester Preis: € 100,99 (vom 07.12.2015)1
BACE - Lead Target for Orchestrated Therapy of Alzheimer's Disease
EN NWISBN: 9780470594070 bzw. 0470594071, in Englisch, John Wiley & Sons, neu.
Lieferung aus: Deutschland, Versandkostenfrei.
BACE: InhaltsangabePREFACE.ACKNOWLEDGMENTS.CONTRIBUTORS.CHAPTER 1 BACE, APP PROCESSING, AND SIGNAL TRANSDUCTION IN ALZHEIMER&apos S DISEASE (Dale E. Bredesen and Edward H. Koo).1.1 Introduction.1.2 BACE Cleavage of APP as a Molecular Switching Mechanism.1.3 AD: An Imbalance in Cellular Dependence 1.4 BACE Cleavage, Caspase Cleavage, and Neuronal Trophic Dependence.1.5 BACE Cleavage of APP, Dependence Receptors, and Alzheimer Pathology.1.6 Key Mutations Proximal of APP Processing to Aβ .1.7 Final Remarks.CHAPTER 2 IDENTIFICATION OF BACE AS A TARGET IN ALZHEIMER&apos S DISEASE (Robert L. Heinrikson and Sukanto Sinha).2.1 Introduction.2.2 The Search for β -Secretase.2.3 Validation of the BACE Target.2.4 Final Remarks.CHAPTER 3 BACE BIOLOGICAL ASSAYS (Alfredo G. Tomasselli and Michael J. Bienkowski).3.1 Introduction.3.2 Clinical and Physiological Hallmarks of Alzheimer’ s Disease (AD).3.3 APP Processing.3.4 Aspartyl Protease Classification.3.5 BACE Structure.3.6 Mechanism, Kinetics, Inhibition, and Specificity.3.7 Assay Strategies for Inhibitor Finding and Development.3.8 Common Assays Used to Identify and Study Inhibitors.3.9 BACE Assays.3.10 Final Remarks.CHAPTER 4 PEPTIDIC, PEPTIDOMIMETIC, AND HTS-DERIVED BACE INHIBITORS (James P. Beck and Dustin J. Mergott).4.1 Introduction.4.2 Elan/Pharmacia (Pfizer).4.3 Oklahoma Medical Research Foundation (OMRF)/Multiple Collaborators.4.4 Eli Lilly.4.5 Merck.4.6 GlaxoSmithKline.4.7 Schering Plough.4.8 Bristol-Myers Squibb.4.9 Novartis.4.10 Amgen.4.11 Wyeth.4.12 Final Remarks.CHAPTER 5 FRAGMENT-BASED APPROACHES FOR IDENTIFICATION OF BACE INHIBITORS (Andreas Kuglstatter and Michael Hennig).5.1 Introduction.5.2 Biophysical Methods Applied to BACE Fragment Screens.5.3 BACE Inhibitors Identified by Fragment Screening.5.4 Final Remarks.CHAPTER 6 STRUCTURE-BASED DESIGN OF BACE INHIBITORS: TECHNICAL AND PRACTICAL ASPECTS OF PREPARATION, 3-DIMENSIONAL STRUCTURE, AND COMPUTATIONAL ANALYSIS (Felix F. Vajdos, Veerabahu Shanmugasundaram, and Alfredo G. Tomasselli).6.1 Introduction.6.2 Preparation of BACE for Structural Studies.6.3 Crystallographic Studies of BACE.6.4 Structural Studies with BACE Inhibitors: Peptidomimetics and Nonpeptidomimetics.6.5 Computational Approaches.6.6 Final Remarks.CHAPTER 7 PHARMACOLOGICAL MODELS FOR PRECLINICAL TESTING: FROM MOUSE TO DOG TO NONHUMAN PRIMATES (Jason L. Eriksen, Michael Paul Murphy, and Elizabeth Head).7.1 Introduction.7.2 BACE1 and Mouse Models of AD.7.3 Testing BACE Inhibitors in the Canine Model of Human Aging and AD.7.4 BACE Inhibitors and Nonhuman Primates.7.5 Final Remarks.CHAPTER 8 ADSORPTION, DISTRIBUTION, METABOLISM, EXCRETION (ADME), EFFICACY, AND TOXICOLOGY FOR BACE INHIBITORS (Ishrut Hussain and Emmanuel Demont).8.1 Introduction.8.2 Development of BACE Inhibitors with Optimized ADME Properties.8.3 In Vivo Efficacy of BACE Inhibitors.8.4 Toxicology of BACE Inhibitors.8.5 Final Remarks.CHAPTER 9 CLINICAL TRIALS FOR DISEASE-MODIFYING DRUGS SUCH AS BACE INHIBITORS (Henry H. Hsu).9.1 Introduction.9.2 Update on Beta-Amyloid Therapies in Clinical Development.9.3 Clinical D Identification of APP Binding Small Molecules that Block β -Site Cleavage of APP.10.8 Final Remarks.AFTERWORD (Ruth Abraham).Introduction.Artwork as a Measure of the Progression of AD.INDEX. Englisch, Ebook.
BACE: InhaltsangabePREFACE.ACKNOWLEDGMENTS.CONTRIBUTORS.CHAPTER 1 BACE, APP PROCESSING, AND SIGNAL TRANSDUCTION IN ALZHEIMER&apos S DISEASE (Dale E. Bredesen and Edward H. Koo).1.1 Introduction.1.2 BACE Cleavage of APP as a Molecular Switching Mechanism.1.3 AD: An Imbalance in Cellular Dependence 1.4 BACE Cleavage, Caspase Cleavage, and Neuronal Trophic Dependence.1.5 BACE Cleavage of APP, Dependence Receptors, and Alzheimer Pathology.1.6 Key Mutations Proximal of APP Processing to Aβ .1.7 Final Remarks.CHAPTER 2 IDENTIFICATION OF BACE AS A TARGET IN ALZHEIMER&apos S DISEASE (Robert L. Heinrikson and Sukanto Sinha).2.1 Introduction.2.2 The Search for β -Secretase.2.3 Validation of the BACE Target.2.4 Final Remarks.CHAPTER 3 BACE BIOLOGICAL ASSAYS (Alfredo G. Tomasselli and Michael J. Bienkowski).3.1 Introduction.3.2 Clinical and Physiological Hallmarks of Alzheimer’ s Disease (AD).3.3 APP Processing.3.4 Aspartyl Protease Classification.3.5 BACE Structure.3.6 Mechanism, Kinetics, Inhibition, and Specificity.3.7 Assay Strategies for Inhibitor Finding and Development.3.8 Common Assays Used to Identify and Study Inhibitors.3.9 BACE Assays.3.10 Final Remarks.CHAPTER 4 PEPTIDIC, PEPTIDOMIMETIC, AND HTS-DERIVED BACE INHIBITORS (James P. Beck and Dustin J. Mergott).4.1 Introduction.4.2 Elan/Pharmacia (Pfizer).4.3 Oklahoma Medical Research Foundation (OMRF)/Multiple Collaborators.4.4 Eli Lilly.4.5 Merck.4.6 GlaxoSmithKline.4.7 Schering Plough.4.8 Bristol-Myers Squibb.4.9 Novartis.4.10 Amgen.4.11 Wyeth.4.12 Final Remarks.CHAPTER 5 FRAGMENT-BASED APPROACHES FOR IDENTIFICATION OF BACE INHIBITORS (Andreas Kuglstatter and Michael Hennig).5.1 Introduction.5.2 Biophysical Methods Applied to BACE Fragment Screens.5.3 BACE Inhibitors Identified by Fragment Screening.5.4 Final Remarks.CHAPTER 6 STRUCTURE-BASED DESIGN OF BACE INHIBITORS: TECHNICAL AND PRACTICAL ASPECTS OF PREPARATION, 3-DIMENSIONAL STRUCTURE, AND COMPUTATIONAL ANALYSIS (Felix F. Vajdos, Veerabahu Shanmugasundaram, and Alfredo G. Tomasselli).6.1 Introduction.6.2 Preparation of BACE for Structural Studies.6.3 Crystallographic Studies of BACE.6.4 Structural Studies with BACE Inhibitors: Peptidomimetics and Nonpeptidomimetics.6.5 Computational Approaches.6.6 Final Remarks.CHAPTER 7 PHARMACOLOGICAL MODELS FOR PRECLINICAL TESTING: FROM MOUSE TO DOG TO NONHUMAN PRIMATES (Jason L. Eriksen, Michael Paul Murphy, and Elizabeth Head).7.1 Introduction.7.2 BACE1 and Mouse Models of AD.7.3 Testing BACE Inhibitors in the Canine Model of Human Aging and AD.7.4 BACE Inhibitors and Nonhuman Primates.7.5 Final Remarks.CHAPTER 8 ADSORPTION, DISTRIBUTION, METABOLISM, EXCRETION (ADME), EFFICACY, AND TOXICOLOGY FOR BACE INHIBITORS (Ishrut Hussain and Emmanuel Demont).8.1 Introduction.8.2 Development of BACE Inhibitors with Optimized ADME Properties.8.3 In Vivo Efficacy of BACE Inhibitors.8.4 Toxicology of BACE Inhibitors.8.5 Final Remarks.CHAPTER 9 CLINICAL TRIALS FOR DISEASE-MODIFYING DRUGS SUCH AS BACE INHIBITORS (Henry H. Hsu).9.1 Introduction.9.2 Update on Beta-Amyloid Therapies in Clinical Development.9.3 Clinical D Identification of APP Binding Small Molecules that Block β -Site Cleavage of APP.10.8 Final Remarks.AFTERWORD (Ruth Abraham).Introduction.Artwork as a Measure of the Progression of AD.INDEX. Englisch, Ebook.
3
BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease (2010)
EN HC NW FEISBN: 9780470293423 bzw. 047029342X, in Englisch, 266 Seiten, Wiley, gebundenes Buch, neu, Erstausgabe.
Lieferung aus: Vereinigte Staaten von Amerika, Usually ships in 1-2 business days.
Von Händler/Antiquariat, BetterWorldBooksUK.
This book covers virtually all aspects of the rapidly developing field of beta secretase (BACE), from the original isolation and cloning of BACE, to the discovery of various classes of BACE inhibitors, to challenges in clinical development. This 360 degree resource provides every member of the diverse drug-discovery team with global understanding essential for productive and successful drug discovery. It also offers researchers and clinicians an overview of the groundbreaking progress that has been made to develop inhibitors of BACE as efficacious treatments for Alzheimer's disease. Hardcover, Ausgabe: 1, Label: Wiley, Wiley, Produktgruppe: Book, Publiziert: 2010-03-15, Studio: Wiley, Verkaufsrang: 5948877.
Von Händler/Antiquariat, BetterWorldBooksUK.
This book covers virtually all aspects of the rapidly developing field of beta secretase (BACE), from the original isolation and cloning of BACE, to the discovery of various classes of BACE inhibitors, to challenges in clinical development. This 360 degree resource provides every member of the diverse drug-discovery team with global understanding essential for productive and successful drug discovery. It also offers researchers and clinicians an overview of the groundbreaking progress that has been made to develop inhibitors of BACE as efficacious treatments for Alzheimer's disease. Hardcover, Ausgabe: 1, Label: Wiley, Wiley, Produktgruppe: Book, Publiziert: 2010-03-15, Studio: Wiley, Verkaufsrang: 5948877.
4
BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease (2010)
EN HC US FEISBN: 9780470293423 bzw. 047029342X, in Englisch, 266 Seiten, Wiley, gebundenes Buch, gebraucht, Erstausgabe.
Lieferung aus: Vereinigte Staaten von Amerika, Usually ships in 1-2 business days.
Von Händler/Antiquariat, -Daily Deals-.
This book covers virtually all aspects of the rapidly developing field of beta secretase (BACE), from the original isolation and cloning of BACE, to the discovery of various classes of BACE inhibitors, to challenges in clinical development. This 360 degree resource provides every member of the diverse drug-discovery team with global understanding essential for productive and successful drug discovery. It also offers researchers and clinicians an overview of the groundbreaking progress that has been made to develop inhibitors of BACE as efficacious treatments for Alzheimer's disease. Hardcover, Ausgabe: 1, Label: Wiley, Wiley, Produktgruppe: Book, Publiziert: 2010-03-15, Studio: Wiley, Verkaufsrang: 5948877.
Von Händler/Antiquariat, -Daily Deals-.
This book covers virtually all aspects of the rapidly developing field of beta secretase (BACE), from the original isolation and cloning of BACE, to the discovery of various classes of BACE inhibitors, to challenges in clinical development. This 360 degree resource provides every member of the diverse drug-discovery team with global understanding essential for productive and successful drug discovery. It also offers researchers and clinicians an overview of the groundbreaking progress that has been made to develop inhibitors of BACE as efficacious treatments for Alzheimer's disease. Hardcover, Ausgabe: 1, Label: Wiley, Wiley, Produktgruppe: Book, Publiziert: 2010-03-15, Studio: Wiley, Verkaufsrang: 5948877.
5
BACE: Lead Target for Orchestrated Therapy of Alzheimer's Disease
EN NWISBN: 9780470293423 bzw. 047029342X, in Englisch, Wiley-Blackwell, neu.
Lieferung aus: Vereinigtes Königreich Großbritannien und Nordirland, 3-5 Days.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
6
BACE
~EN NW EB DLISBN: 9780470594070 bzw. 0470594071, vermutlich in Englisch, BACE, neu, E-Book, elektronischer Download.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
7
Symbolbild
BACE (2010)
EN NWISBN: 9780470293423 bzw. 047029342X, in Englisch, Wiley John & Sons Mrz 2010, neu.
Von Händler/Antiquariat, Agrios-Buch [57449362], Bergisch Gladbach, Germany.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
9
BACE
EN NW EB DLISBN: 9780470594070 bzw. 0470594071, in Englisch, Wiley, Vereinigte Staaten von Amerika, neu, E-Book, elektronischer Download.
Lieferung aus: Deutschland, zzgl. Versandkosten.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
10
BACE. Lead Target for Orchestrated Therapy of Alzheimer's Disease
~EN NW EB DLISBN: 9780470594070 bzw. 0470594071, vermutlich in Englisch, John Wiley & Sons Limited, neu, E-Book, elektronischer Download.
Lieferung aus: Russische Föderation, zzgl. Versandkosten.
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Die Beschreibung dieses Angebotes ist von geringer Qualität oder in einer Fremdsprache. Trotzdem anzeigen
Lade…